PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 22 filers reported holding PHARVARIS N V in Q1 2023. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $78,125,802 | +37.8% | 3,743,450 | 0.0% | 43.39% | +55.7% |
| Q2 2023 | $56,675,833 | +116.7% | 3,743,450 | +15.3% | 27.86% | +105.3% |
| Q1 2023 | $26,153,989 | -28.4% | 3,246,926 | 0.0% | 13.57% | -13.0% |
| Q4 2022 | $36,527,918 | +46.7% | 3,246,926 | 0.0% | 15.60% | +94.8% |
| Q3 2022 | $24,904,000 | -65.3% | 3,246,926 | 0.0% | 8.01% | -58.5% |
| Q2 2022 | $71,757,000 | +21.3% | 3,246,926 | -0.5% | 19.32% | +16.8% |
| Q1 2022 | $59,155,000 | +26.0% | 3,261,926 | 0.0% | 16.55% | +71.4% |
| Q4 2021 | $46,939,000 | -18.8% | 3,261,926 | 0.0% | 9.66% | +13.4% |
| Q3 2021 | $57,834,000 | -4.8% | 3,261,926 | 0.0% | 8.52% | +3.7% |
| Q2 2021 | $60,770,000 | -33.4% | 3,261,926 | 0.0% | 8.21% | -24.9% |
| Q1 2021 | $91,269,000 | – | 3,261,926 | – | 10.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,261,926 | $60,770,000 | 8.21% |
| venBio Partners LLC | 2,303,310 | $42,911,000 | 5.06% |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $59,255,000 | 3.88% |
| Foresite Capital Management V, LLC | 364,142 | $6,784,000 | 2.67% |
| VR Adviser, LLC | 902,882 | $16,821,000 | 2.04% |
| Cormorant Asset Management, LP | 744,863 | $13,634,000 | 0.46% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,032,757 | $19,240,000 | 0.34% |
| GENERAL ATLANTIC, L.P. | 2,420,155 | $45,087,000 | 0.32% |
| Opaleye Management Inc. | 79,837 | $1,487,000 | 0.25% |
| Avidity Partners Management LP | 400,000 | $7,452,000 | 0.20% |